RLAY
NASDAQ · Biotechnology
Relay Therapeutics Inc
$9.56
-0.26 (-2.65%)
Financial Highlights (FY 2026)
Revenue
12.36M
Net Income
-417,234,202
Gross Margin
—
Profit Margin
-3,374.7%
Rev Growth
+48.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 61.2% | 61.2% |
| Operating Margin | -3,722.1% | -3,349.9% | 34.0% | 31.7% |
| Profit Margin | -3,374.7% | -3,206.0% | 20.5% | 21.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 12.36M | 8.30M | 220.69M | 215.28M |
| Gross Profit | — | — | 135.02M | 131.71M |
| Operating Income | -459,887,616 | -277,933,692 | 75.10M | 68.21M |
| Net Income | -417,234,202 | -252,156,044 | 45.13M | 45.09M |
| Gross Margin | — | — | 61.2% | 61.2% |
| Operating Margin | -3,722.1% | -3,349.9% | 34.0% | 31.7% |
| Profit Margin | -3,374.7% | -3,206.0% | 20.5% | 21.0% |
| Rev Growth | +48.9% | +48.9% | +11.7% | +6.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 477.64M | 487.30M |
| Total Equity | — | — | 867.00M | 902.73M |
| D/E Ratio | — | — | 0.55 | 0.54 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -453,401,089 | -289,236,526 | 96.01M | 91.95M |
| Free Cash Flow | — | — | 41.24M | 69.53M |